We are pleased to announce a seminar for medical institutions to provide the latest information on treatments using deciduous tooth pulp stem cell culture supernatant (SGF). Our affiliated medical facilities have accumulated a significant track record since 2016, with approximately 7,000 cases (including cosmetic dermatology, around 12,000 cases), along with numerous effective case studies and precise data verification through collaborative research with academia.
We currently have data suggesting the effectiveness of our treatment in the context of COVID-19 infection. Our CEO, Shoji Koga, will provide an explanation of this information. Additionally, we plan to share recent monitoring data utilizing the Lox-index for SGF in this seminar. We hope that you will join us and find valuable insights into the latest developments in deciduous tooth pulp stem cell culture supernatant (SGF) and exosome therapy.

【Event Details】
□ Date
June 5, 2022 (Sunday)

□ Time
10:30 AM – 11:30 AM (Registration: 10:00 AM)

□ Venue
To be conducted via Zoom
(Additional details will be provided after registration.)

□ Speaker
Shoji Koga
Founder, Panajee Co., Ltd.
Special Advisor, Solaria Clinic Group

□ Participation Fee
Free (Limited to the first 30 attendees)

【Seminar Agenda】
・ Latest Information on Deciduous Tooth Pulp Stem Cell Culture Supernatant (SGF)
・ Treatment Case Studies and Research Achievements
・ Recent Monitoring Data on SGF

【Registration】
To apply via the website, please click here.

For fax applications, use this form: 0120-310-644
To apply via email, send your request to: info@solaria.tokyo
For inquiries and phone registrations, please contact:Solaria Clinic Group SGF Office at 03-5809-7979

Organized by: Solaria Clinic Group and Panajee Co., Ltd.
Supported by: Social Welfare Corporation Jinseikai Edogawa Hospital, Japan Society for Pioneering Regenerative Medicine, and others.